Jordi Aparici Market Intelligence Consultant

Similar documents
ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

Pharmamarketing - strategic challenges

Principles of Pharmaceutical Marketing for Non-Marketing Functions

Breaking the Silo Mentality Working With Opinion Leaders

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016

Forecasting strategies and success factors. March 21, 2017

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

Pharma Medical Affairs 2020 and beyond. Matthias Evers Edd Fleming Arnab Ghatak Jan Hartmann Arif Nathoo Ron Piervincenzi Lawrence Wai Ann Westra

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

SAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014

WHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs

Update on Real World Evidence Data Collection

Brazil Gastric Balloon Procedures Outlook to 2020

Strategy & Planning for Commercial Launch Success in Pharma A Cross-functional Approach

Investor Update. Jefferies Global Healthcare Conference June Because people depend on us

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges

Commercial Pricing and Contracting 101

Medical Affairs for Modern Pharma New Challenges & Competencies

Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go

Planning of Application

ABPI response to European Commission consultation on advanced therapy medicinal products

The Role of Medical Affairs in a Successful Commercial Launch A FirstWord Dossier ExpertViews Report

The Future of Market Access A FirstWord ExpertViews Dossier Report

RWE Market Impact on Medicines: A Lens for Pharma

Brand Plan Sample Template. Akademia Marketingu Farmaceutycznego

Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity

MATRIX INTELLIGENT MARKET INSIGHTS, ACROSS YOUR PRODUCT LIFECYCLE

Implementing Benefit-Risk Management More Effectively

France Pressure Relief Devices Market Outlook to 2020

Do We Need Medical Affairs?

Reinforce, expand, refocus Ashfield s syndicated services

FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY

How to Make Your Drug Launch a Success

New Complexities in Pricing Orphan and Ultra-Orphan Drugs

Trinity ConTRact: Cornerstone Projects in Contracting Strategy

Value of Industry Pharmacists (VIP) Case Competition ( ) Competition Guide Version 2.0. This year s competition is sponsored by:

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

Portfolio Marketing. Research and Advisory Service

Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020

REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Opportunities in the Health Care Practice at Analysis Group

Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017

REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

Joint Horizon Scanning for pharmaceuticals

@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015

BRIC Surgical Sutures Market Outlook to 2020

Data and Analytics Unlocking Future of Pharma Sales Planning. Maria Kliatchko

ZS Medical Affairs Outlook Report Analysis of Field Medical Growth and Industry Trends

Complex Generics: Charting a new path

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY

Adaptive Pathways. Goals of EMA and National Competent Authorities. Harald Enzmann

ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014

White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act

Pharma EXPO 6 9 November 2016 Chicago, IL

DRUG DEVELOPMENT TARGET PRODUCT PROFILE

Diversifying the MSL-KOL Relationships: The Prominent Rise of the Pharmacist KOLs Key Study Findings

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Social Media in Healthcare Leverage Social Media for Real Business Impact

Pharmaco-Epidemiological Studies. A French experience

Mapping the Patient Journey: Harnessing the power of big data and analytics A FirstWord ExpertViews Dossier Report

Decoding Phase II Clinical Trial Terminations

Insights into the Evolving Pricing & Market Access Environment

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

The Value Adding Medical Science Liaison

How to Reward Innovation and Value in Comparative Effectiveness Research

Exploring Practical Implementation of Economic Incentives for Antimicrobial Development in the U.S.

.COM. Pharmaceutical Brand Management Achieving Managed Care Pull-Through Performance

Using local RWD to drive global therapeutic advancements.

Key Opinion Leader Development. Tony Moses President, A-Z Eye Consultants National Manager, eyecheck LLC

Case Commentary. Innovative marketing strategies after patent expiry

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005

HOW TO lead IN THE DIGITAL AGE

Helping unlock growth opportunities worldwide

Partnering with Rare Disease Patient Groups. Namrata Taak R&D External Communications, Rare Diseases

4/26. Analytics Strategy

Healthcare s New Change-Maker: The CFO

Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024

REFERENCE CODE GDHC54PIDR PUBLICATION DATE JULY 2013 POSTMENOPAUSAL VAGINAL ATROPHY - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022

Aligning internal teams to secure buy-in from external stakeholders: a critical part of launch strategy

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013

International Transfers of Personal Data at sanofi-aventis R & D

Four entry strategies for small and midsized companies

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

Building Strong Cross functional Medical Affairs Teams A FirstWord Dossier ExpertViews Report

Global Recruiting Trends What you need to know about the state of talent acquisition

LexisNexis Health Care data delivered within PlayMaker CRM sales platform

your guide to boosting booth presence

Channel Incentive Study B2B Technology Industry

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

CLINICAL TRIALS AND MARKET RESEARCH

The Strategic Digital Pharma Marketing Course

DIGITAL EDITION BONUS CONTENT

The Pharma Brand Planning Course

Business Case Template

Transcription:

Jordi Aparici Market Intelligence Consultant Helping pharma companies make robust decisions based on market, competitors and patient knowledge Market Intelligence Strategy Marketing Market Research Data Analytics Competitive Intelligence Forecasting Portfolio Planning Sales Force Excellence Business Development & Licensing Market Access jordi.aparici@hotmail.com 1

2

3

Market knowledge is key from the very beginning The marketing role in the pipeline lifecycle Preclinical Ph I Ph IIa Ph IIb Ph III Registration Price & Reimb Launch 4

Market knowledge is key from the very beginning The marketing role in the pipeline lifecycle Preclinical Ph I Ph IIa Ph IIb Ph III Registration Price & Reimb Launch Brand Strategy Decisions: Product market research (landscape, product profile test, positioning test ) Target group Positioning strategy Comunication strategy Sales forecasting. Business case. Quantify potential patient population Pricing and Reimbursement Strategy: Payer research Price corridors Market Access Strategy Development Value dossier HTA assessment SmPC Geographies: Identify key global markets KOL network 5

Market knowledge is key from the very beginning The marketing role in the pipeline lifecycle Preclinical Ph I Ph IIa Ph IIb Ph III Registration Price & Reimb Launch Marketing Tactics Identify value messages that best resonate with doctors, payers and KOLs Master Visual Aid Local adaptation Key target audience Education and disease awareness Pricing & R. negotiation with P&R authorities Country Market Access Strategy. Local Value dossier Sales Force Sizing and Training 6

Market knowledge is key from the very beginning The marketing role in the pipeline lifecycle Preclinical Ph I Ph IIa Ph IIb Ph III Registration Price & Reimb Launch Implementación del plan táctico Monitorizacion, market research: ATU, DFU, KPIs, posicionamiento 7

Market knowledge is key from the very beginning The marketing role in the pipeline lifecycle Preclinical Ph I Ph IIa Ph IIb Ph III Registration Price & Reimb Launch Market Landscape assessment Identify treatment paradigms Benchmark competitive market Understand unmet needs Assess pipeline Steakholders Quantify Market & Opportunity Potential TPP, dtpp definition. Value proposition. Product positioning and indication Assess payers reactions to potential drug profile and trial design R&D resources prioritization 8

Defining the desired product dtpp (disease target product profile) 9

Defining the desired product dtpp (disease target product profile) 10 10

Defining the desired product TPP (target product profile) Product ID: XXXX Level of innovation: XXX Characteristics Minimum (MAPP) Target (TPP) Competitor* (CPP) Reference product Indication (primary & secondary) Target patient population Dosing Formulation & delivery mechanism Efficacy (Primary & secondary end points, QoL) Safety & tolerability (side effects & interactions) Contraindications Price Opportunity window 11

Projects Prioritization R&D Attractiveness Commercial Attractiveness Dimensions Prevalence Unmet need Variables Xxx Xxx Xxx Xxx Weight 20% 10% 40% 30% Criteria for score Xxx Xxx Xxx Xxx Fit w/ Company R&D Capabilities Fit w/ Company Commercial Capabilities Market Access Pricing Market and product size 12

Projects Prioritization Dimensions Proj. X36 Proj. Y21 Proj.Y52 Proj. Z18 Prevalence Unmet need Commercial Attractiveness Market Access Pricing Market and product size R&D Attractiveness Fit w/ Company Commercial Capabilities Fit w/ Company R&D Capabilities 13

Market Info Needed q What are the trends in the patient population? Prevalence? Incidence? q What is the diagnosis rate? What is the treatment rate? Do patients actively seek treatment? q Is your product effective only in a subpopulation? q What are the patient unmet needs? q Is treatment driven by specialists or primary care? Subspecialties? Hospital- or office-based? q Are guidelines in place? q Physician unmet needs q Is the current treatment paradigm changing?. What is doctor s perception on current products? q Who is the primary payer? Cash? Private Insurance? q Which is the price corridor? q What are the products used today? Level of use. Place in the Are there significant discounts line of therapy and rebates required? q Are there other developments in pipeline? What unmet need q Will price affect volume? Any are they solving? patient co-pay? Model Type Selection, Uptake q What differentiates my product from the competition? Parameters, & Treatment q Do we foresee Assumptions reimbursement/market access q What is the size of the market? And product potential? restrictions? 14

Methodology and Sources Primary sources: Internet: clinicaltrials.gov, EMA, FDA, Epidemiology data Global supliers: IMS, Datamonitor, Decision Resources, Global Data, Milenium, Pipeline Databases, etc Real World Data, Big Data Secondary sources Market Research (quant/qual) (including Payers) Competitive Intelligence Congresses ü Market Understanding Research ü Product Profile Test ü Patient Unmet Needs Forecasting 15

Forecasting Sizing the potential of the new product Patient-based (Bottom Up) Prevalence Sales-based (Top Down) Units Sold (IMS) Market Size Diagnosed Treated Treated for the Specific Disease Segment Units sold (for the Specific Diagnose) Days of Treatment Patients Treated Patient Pool Product Share Conversion to Sales Product X Patient Share (at peak) Market Access burden Days of Treatment Price / Reimbursement Sales (at peak) 16

Take home message: Assess the market from the very beginning so that your projects are market oriented 17

18

Costumer Centricity See the world as our customer does Product Centric Company Customer Centric Company NEW PRODUCT DEVELOPMENT Create the best product, best tecnology, best design, better that competitors CUSTOMER EXPERIENCE MANAGEMENT Understand howshe feels, discover unmet needs, solve customer problems and engage them 19

Costumer Centricity See the world as our customer does 1. Observe and Understand 2. Idea and Design 3. Implement ation 20

1. Observe and Understand 2. Idea and Design 3. Implement ation 21

Ethnographic Market Research 22

Patient Journey Touch points identification and understanding 23

1. Observe and Understand 2. Idea and Design 3. Implement ation 24

Patient Journey Map Identification of potential interventions Selection and Prioritization Draft design Co-creation sessions 25

1. Observe and Understand 2. Idea and Design 3. Implement ation 26

Customer Centricity Implementation Mindset change Classification and priorization of interventions Prepare the action plan Cultural transformation 27

Video Almirall 28

29

Take Home Messages Assess the market from the very begining so that your projects are market oriented See the world as your customer does It will bring new product ideas You will improve the interaction with customers Customer engagement 30

Jordi Aparici Market Intelligence Consultant jordi.aparici@hotmail.com Market Intelligence Strategy Marketing Market Research Data Analytics Competitive Intelligence Forecasting Portfolio Planning Sales Force Excellence Business Development & Licensing Market Access 31